Le dasatinib augmente le risque d'hémorragies
Voir l'article du journal Blood:
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
Alfonso Quintas-Cardama, Xin Han, Hagop Kantarjian, and Jorge Cortes* Blood First Edition Paper, prepublished online May 4, 2009; DOI 10.1182/blood-2008-09-180604.
'Dasatinib is associated with increased risk of bleeding among patients with chronic myeloid leukemia (CML), even in the absence of thrombocytopenia, suggesting the presence of a hemostatic defect.'
http://bloodjournal.hematologylibrary.o ... type=HWCIT